Nektar Therapeutics Bets Big on Respag Phase 3

Nektar Therapeutics ((NKTR)) has held its Q4 earnings call. Read on for the main highlights of the call.

Nektar Therapeutics’ latest earnings call struck a cautiously optimistic tone, as management highlighted strong clinical wins for Respag alongside a significantly fortified balance sheet. Executives framed 2025 as a pivotal de‑risking year clinically, even as they acknowledged heavy losses, rising R&D spend, and multi‑year timelines that keep execution and cash‑burn risks firmly in focus.

Phase 2b Wins Validate Respag and Treg Mechanism

Respag delivered the first positive Phase 2b data in both atopic dermatitis and alopecia areata, positioning it as a late‑stage, novel mechanism candidate. Management argued that the results validate the Treg‑based approach and support moving the asset into registration‑enabling studies in diseases where biologics are already well established.

Durable 36-Week Efficacy and Deepening Responses

In atopic dermatitis, 36‑week maintenance data showed not only durable efficacy but also deepening responses with continued monthly or quarterly dosing. The company reported rising EASI‑75 and EASI‑90 rates over time and highlighted up to a roughly fivefold increase in EASI‑100, suggesting that longer treatment could unlock near‑complete disease clearance for more patients.

Expansive Safety Database and Differentiated Profile

Nektar now has safety data on more than 1,000 Respag‑treated patients, representing about 381 patient‑years of exposure. Management emphasized a differentiated safety profile to date, noting no evident increase in systemic adverse events such as conjunctivitis, serious infections, or malignancies, key concerns for many existing immunology therapies.

Phase 3-Ready With Clear Regulatory Milestones

The company has secured alignment with the FDA on Phase 3 dosing and key trial design elements in atopic dermatitis, removing a major regulatory overhang. First patient randomization is targeted for June 2026, with the initial pivotal readout expected in mid‑2028 and a potential biologics license application submission penciled in for 2029.

Dosing Convenience and Device Plan Aim for Commercial Edge

Respag’s potential for monthly or even quarterly maintenance dosing is central to Nektar’s commercial pitch in an increasingly crowded field. The firm plans to launch the drug, if approved, via an auto‑injector with weight‑banded dosing, designed for simple self‑administration and intended to mimic the ease of use of single‑use pen devices already familiar to patients.

Strengthened Cash Position Supports Costly Phase 3 Push

Nektar ended 2025 with $245.8 million in cash and investments and no debt, then raised roughly $476 million net via an equity offering and ATM facility. Management now expects to finish 2026 with about $400 million to $460 million in cash, giving the company runway to fund Phase 3 execution despite the looming spike in development spending.

Pipeline Expansion Beyond Atopic Dermatitis and Alopecia

Beyond Respag in skin disease, a TrialNet‑sponsored Phase 2 study in new‑onset type 1 diabetes is underway, with initial data expected in 2027. Preclinical TNFR2 agonist and bispecific programs, NKTR‑0165 and NKTR‑0166, are moving toward planned INDs in 2027, while management is also evaluating additional autoimmune indications such as asthma, chronic rhinosinusitis, and dermatomyositis.

Commercially Relevant Signals in Asthma and Patient-Reported Outcomes

Respag produced statistically significant gains on ACQ‑5 asthma control scores in atopic dermatitis patients who had comorbid asthma, including roughly 75% improvement in those with uncontrolled disease at baseline. The drug also delivered rapid itch relief and favorable patient‑reported outcomes, which could translate into tangible real‑world value if reproduced in larger trials.

Heavy Net Losses Underscore Ongoing Cash Burn

Financially, Nektar remains deep in the red, with a 2025 net loss of $164.1 million, or $9.73 per share, and a fourth‑quarter loss of $36.1 million, or $1.78 per share. These figures underscore that the story is still firmly in the investment phase, with little revenue contribution today to offset the growing clinical spend.

R&D Spending Set to Surge in 2026

Management guided 2026 R&D expenses to a hefty $200 million to $250 million, up sharply from $117.3 million in 2025 as Phase 3 preparations ramp. That roughly 70% to 113% increase highlights both the scale of the planned late‑stage program and the near‑term pressure on cash burn that investors must weigh against the long‑term payoff.

Rising Non-Cash Interest to Weigh on Reported Results

Non‑cash interest expense reached $26.2 million in 2025 and is expected to climb to $30 million to $35 million in 2026. While this charge does not affect cash, it will further depress reported earnings and illustrates how the company’s capital structure continues to shape headline financial performance.

Wide Guidance Ranges Reflect Planning Uncertainty

Nektar’s 2026 guidance came with notably wide ranges, including R&D of $200 million to $250 million and projected year‑end cash of $400 million to $460 million. Management attributed the spread to uncertainties around Phase 3 timing and operational planning, signaling that actual spending could swing meaningfully within those bands.

Injection Site Reactions Remain a Key Safety Watchpoint

Injection site reactions were common across the Respag program, though approximately 99% were mild to moderate and mostly erythema, with about 1% classified as severe. The company views these events as manageable but acknowledged that clear communication and mitigation strategies will be essential, particularly in a chronic outpatient setting.

Litigation and External Risks Add Background Overhang

Management highlighted ongoing litigation as an unresolved overhang that could ultimately carry financial or operational consequences. While no outcome was speculated on, the pending case adds another layer of uncertainty for shareholders on top of the already complex clinical and competitive backdrop.

Competitive and Timing Challenges in a Crowded Field

Respag will have to carve out space alongside established agents such as Dupixent, IL‑13 inhibitors, and JAKs, which offer strong efficacy despite safety and monitoring issues. With Phase 3 data not expected until mid‑2028 and a potential filing in 2029, Nektar faces years of execution risk and the possibility that new multispecific agents from larger players could reshape the market before launch.

Forward Guidance: Funding the Long March to Phase 3

For 2026, Nektar expects non‑cash royalty revenue of $40 million to $45 million, R&D of $200 million to $250 million, G&A of $60 million to $65 million, and non‑cash interest expense of $30 million to $35 million. The company forecasts year‑end 2026 cash and investments of approximately $400 million to $460 million, assuming successful execution of Phase 3 startup activities and first patient randomization in June.

Nektar’s call painted the picture of a company transitioning firmly into late‑stage development, with compelling Respag data and a fortified cash position offset by large losses and multi‑year risks. For investors, the story now centers on Phase 3 execution, managing 2026 burn, and whether the program’s safety and durability can ultimately translate into commercial traction in a competitive market.